Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;55(3):954-958.
doi: 10.1007/s12020-016-1185-1. Epub 2016 Nov 23.

Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy

Marina S Carvalho  1 , Pedro W Rosario  2 , Gabriela F Mourão  1 , Maria R Calsolari  1
Affiliations

Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy

Marina S Carvalho et al. Endocrine. 2017 Mar.

Abstract

Background: This study evaluated the recurrence in patients with papillary thyroid cancer and an excellent response to initial therapy, comparing those with and without chronic lymphocytic thyroiditis.

Methods: This was a prospective study. Patients who met the following criteria were selected: diagnosis of papillary thyroid cancer; submitted to total thyroidectomy followed or not by ablation with 131I; and neck ultrasonography without abnormalities, nonstimulated thyroglobulina (Tg) ≤0.2 ng/ml, and undetectable antithyroglobulin antibodies (TgAb) 12-18 months after initial therapy. The patients were divided into two groups: group A, with chronic lymphocytic thyroiditis on histology; group B, without chronic lymphocytic thyroiditis on histology.

Results: Groups A and B were similar in terms of sex and age of the patients, characteristics of the tumor, tumor-node-metastase stage and risk category. The time of follow-up ranged from 24 to 120 months (median 66 months). During follow-up, 5 patients of group A (2.6 %) and 9 patients of group B (2 %) developed recurrence (p = 0.77). Patients with chronic lymphocytic thyroiditis were more likely to progress to persistently borderline TgAb. No patient had positive TgAb (above the reference value) during follow-up. Recurrences occurred in 12/588 patients (2 %) with undetectable TgAb in all measurements, in 1/32 (3.1 %) with detectable TgAb on some occasion but that returned to undetectable spontaneously, and in 1/13 (7.7 %) with persistently borderline TgAb. These rates did not differ significantly (p = 0.25).

Conclusion: The results of the present study showed the absence of an association between chronic lymphocytic thyroiditis and recurrence risk at least in patients with an excellent response to initial therapy.

Keywords: Chronic lymphocytic thyroiditis; Excellent response to therapy; Papillary thyroid cancer; Recurrence.

PubMed Disclaimer

References

    1. Thyroid. 2014 Mar;24(3):488-93 - PubMed
    1. Thyroid. 2014 Jul;24(7):1139-45 - PubMed
    1. Eur J Endocrinol. 2013 Feb 15;168(3):343-9 - PubMed
    1. Endocr Pract. 2014 Apr;20(4):293-8 - PubMed
    1. Thyroid. 2016 Apr;26(4):525-31 - PubMed

LinkOut - more resources